online adaptive radiotherapy: Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
Study summary
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Biopsy-verified anal cancer
* Eligible for curative intended radiotherapy
* Written and oral consent
Exclusion Criteria:
* Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Primary outcome measure(s)
Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest) — from mid-treatment to 3 months after end of treatment percentage of patients with grade 2 or more early treatment-related Gastrointestinal-toxicity
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.